Big pharma's interest in linkurl:stem cell research;http://www.the-scientist.com/blog/display/54900/ is picking up speed. Pharmaceutical giant Pfizer is expanding its research into the technology and plans to open a second regenerative medicine unit in Cambridge, UK, this November, Reuters linkurl:reported;http://www.reuters.com/article/reutersEdge/idUSTRE48MBY020080923?sp=true yesterday. Pfizer isn't the only one. In July, GlaxoSmithKline entered a linkurl:5-year, $25 million collaboration;http://www.gsk.com/media/pressreleases/2008/2008_pressrelease_10089.htm with the Harvard Stem Cell Institute. In the spring, Pfizer opened a regenerative medicine unit in Cambridge, Massachusetts, focusing on stem cells for cardiac disorders and cancer, according to the linkurl:company's Web site.;http://www.pfizer-regenerativemedicine.com/locations/index.php The new UK site will eventually house 60 scientists and research will focus on age-related and degenerative and nervous system disorders. While Pfizer's stem cell research policy does not rule out the use of embryonic stem cells, the company is also extremely interested in induced pluripotent stem (iPS) cells, John McNeish, head of the Massachusetts operation, told Reuters at the World Stem Cell Summit, held...
Interested in reading more?
Become a Member of
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
